Navigation Links
Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
Date:4/16/2008

CALGARY, April 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan Melcher and his research group at St. James's University Hospital in Leeds, U.K. published the results of their work in the April 10 online issue of Gene Therapy. The paper is entitled "Inflammatory Tumour Cell Killing by Oncolytic Reovirus for the Treatment of Melanoma."

The investigators showed that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour. They demonstrated that reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death. They concluded that reovirus is suitable for clinical testing in melanoma.

"Our ongoing preclinical work indicates that reovirus has a number of mechanisms by which it kills melanoma cell lines and tumours," said Dr. Brad Thompson, President and CEO of Oncolytics. "This most recent work provides additional support to our upcoming Phase II melanoma clinical trial with the U.S. National Cancer Institute."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials published in "Gene Therapy" with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigat
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
2. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
3. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
5. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
6. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
7. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
9. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
10. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
11. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2008)...y company to offer choice of two distinct drugs on...orms, NATICK, Mass., July 2 /PRNewswire-FirstCall...oday announced that the U.S. Food and Drug,Adminis...us-Eluting,Coronary Stent System for the treatment... private-labeled XIENCE(TM) V Everolimus-Eluting C...
(Date:7/2/2008)...ming soon to Bioniche,s growing line of injectable...REST, Ill., July 2 /- Bioniche Pharma...le pharmaceuticals, announced today,the acquisitio... line,including:, -- ENLON(R) (edrophonium chl...ON-PLUS(R) (edrophonium chloride, USP and atropine...
(Date:7/2/2008)... Northeastern University Technology Receive Fundin...logy for the Extraction of ...Allied Minds, a pre-seed investment,corporation sp...ures,Harvard University,s Office of Technology De...e creation of CryoXtract Instruments, LLC, a new,s...
(Date:7/2/2008)... potential of pre-treatment R2 levels as a possibl...y -, TORONTO, July 2 / Lor..." or the "Corporation"), a biopharmaceutical compa... pharmaceutical products and,technologies for the ...by,an Ohio State University (OSU) clinical team of...
Breaking Biology Technology:Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R) 2Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5
...oday, for the first time, China has 100 million pe...oadband. Within a few years, a billion people in A...r and all that technology replicating at a phenome...de and communications. , ,The entire continent of ...ulated countries, is not far behind. The process o...
...CHICAGO Its that time again for the half-year ro...d the U.S. life sciences sector. If you recall the...mal for the major indices: , , Dow Jones down 3 pe...sdaq Biotech down 16% percent , Amex Biotech down ...ee below, the results for the first six months of ...
...LWAUKEE - Niceware International, a supplier of...C) software, announced on Monday they have introdu...e new versions of NL offerings include support for...ation (RFID) tags, as well as an improved user int...ith Windows programs such as Microsoft Access, Win...
...uston - As NASA works to get the Space Shuttle D...rmation of the astronauts will be monitored by NAS... heart monitoring and digital networking systems. ...tor and track the health of the astronauts during ...formation with experts located outside NASA,s miss...
Other Biology Technology:Huge cyber-tsunami developing in Asia 2Huge cyber-tsunami developing in Asia 3Midwest large cap life sciences mostly outperform market 2Midwest large cap life sciences mostly outperform market 3
(Date:7/3/2008)...is, a GlaxoSmithKline company focused on discoveri...seases of aging such as Type 2 Diabetes, is includ...online edition of Cell Metabolism that mice trea...rol showed an overall health improvement, includin...nd cardiovascular dysfunction, and improved balanc...
(Date:7/3/2008)...tudied the regeneration of the tropical forest in ...te to tropical forest, but only slowly. Two proced...iage to free up space for trees and planting the d...odel to calculate the appropriate measures. , P...s and services the forest supplies. However, the n...
(Date:7/3/2008)...t, eventually, bacteria outsmart them and become r...uch resistance, a new drug may be able to finally ...ted the new drug, called Ceftobiprole, against som...Staphylococcus aureus (MRSA) bacteria, which are r...l infections worldwide, both in hospitals and in t...
(Date:7/2/2008)... by a bold commitment from Germany, leaders of the... the upcoming G8 Summit in Japan to take immediate... German Chancellor Angela Merkel,s recent pledge ...ropical forests, followed by increased annual spen...or source of greenhouse gas emissions causing clim...
Breaking Biology News(10 mins):Long-term study of middle-aged mice shows 2Long-term study of middle-aged mice shows 3Giving nature a helping hand 2New antibiotic beats superbugs at their own game 2G8 summit: Opportunity for immediate action on climate change 2G8 summit: Opportunity for immediate action on climate change 3GeoVax Successful HIV AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference 255 1GeoVax Successful HIV AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference 255 2GeoVax Successful HIV AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference 255 3GeoVax Successful HIV AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference 255 4Shrinkage of prostate led to overestimation of cancer risk in trial 1100 1Shrinkage of prostate led to overestimation of cancer risk in trial 1100 2Herr receives Heinz Award for Technology the Economy and Employment 361 1Herr receives Heinz Award for Technology the Economy and Employment 361 2Herr receives Heinz Award for Technology the Economy and Employment 361 3Herr receives Heinz Award for Technology the Economy and Employment 361 4Office Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens Young Adults 1095 1Office Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens Young Adults 1095 2Office Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens Young Adults 1095 3Office Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens Young Adults 1095 4Office Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens Young Adults 1095 5
...me researchers didn,t think what we were attemptin...th University and Mol-Switch project coordinator, ...Emerging Technologies initiative. "However, we got...at the Mol-Switch project was far more successful ...er of DNA-based motors and can achieve incredible ...
...em bigger than life ?big bones, big mysteries. So ...bout dinosaurs may come from small ?very small ?re...gan State University zoologist Peggy Ostrom. "We,v... and proteins can tell us about diseases, about wh...t they ate and who they are related to." , Ostrom...
...e than 100 people have been infected with the H5N1...with infected poultry, the fact that the virus doe...s to other humans has been a biomedical puzzle. , ...ct reveals a simple anatomical difference in the c... virus to jump from human to human. , The finding...
...at Texas A&M University have successfully "kno...ing genes in a cloned goat fetus, perhaps paving t...imals, even those genes that might cause bovine sp...ad Cow Disease. , Researchers Mark Westhusin and C...ry Medicine & Biomedical Sciences, working wit...
Other Biology News:Nano machine switches between biological and silicon worlds 2Nano machine switches between biological and silicon worlds 3Next good dinosaur news likely to come from small packages 2Cell barrier shows why bird flu not so easily spread among humans 2Cell barrier shows why bird flu not so easily spread among humans 3Successful cell engineering may lead to mad cow prevention, say researchers 2
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells
Agarose overlays are commonly used in baculovirus plaque assays. Many commercial "DNA grade" agaroses either contain contaminants that are toxic to insect cells or lack the physical characteristics r
AgarPlaque Plus Agarose 50 grams
Dithiothreitol, 1M from Upstate
Biology Products: